relapsing remitting multiple sclerosis

Summary

Summary: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)

Top Publications

  1. ncbi European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Gla
    G Comi
    Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy
    Ann Neurol 49:290-7. 2001
  2. pmc The relation between inflammation and neurodegeneration in multiple sclerosis brains
    Josa M Frischer
    Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, A 1090 Wien, Austria
    Brain 132:1175-89. 2009
  3. ncbi Axonal loss in normal-appearing white matter in a patient with acute MS
    C Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 57:1248-52. 2001
  4. ncbi Cytokine mRNA expression in patients with multiple sclerosis and fatigue
    Peter Flachenecker
    Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Mult Scler 10:165-9. 2004
  5. ncbi Secondary progressive multiple sclerosis: current knowledge and future challenges
    Marco Rovaris
    Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
    Lancet Neurol 5:343-54. 2006
  6. ncbi Defining interferon beta response status in multiple sclerosis patients
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 56:548-55. 2004
  7. ncbi Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
    L K Fisniku
    NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Brain 131:808-17. 2008
  8. ncbi Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
    R Zivadinov
    Department of Clinical Medicine and Neurology, University of Trieste, Italy
    Neurology 57:1239-47. 2001
  9. ncbi Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis
    Maja Eriksson
    Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden
    Mult Scler 9:260-74. 2003
  10. ncbi Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
    Annette Langer-Gould
    Department of Neurology, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:375-81. 2005

Detail Information

Publications265 found, 100 shown here

  1. ncbi European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Gla
    G Comi
    Department of Neuroscience, Scientific Institute Ospedale San Raffaele, University of Milan, Italy
    Ann Neurol 49:290-7. 2001
    ..randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS)...
  2. pmc The relation between inflammation and neurodegeneration in multiple sclerosis brains
    Josa M Frischer
    Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna, Spitalgasse 4, A 1090 Wien, Austria
    Brain 132:1175-89. 2009
    ..It further indicates that the disease processes of multiple sclerosis may die out in aged patients with long-standing disease...
  3. ncbi Axonal loss in normal-appearing white matter in a patient with acute MS
    C Bjartmar
    Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, OH 44195, USA
    Neurology 57:1248-52. 2001
    ..Axonal number and appearance was normal in ascending sensory tracts. CONCLUSIONS: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS...
  4. ncbi Cytokine mRNA expression in patients with multiple sclerosis and fatigue
    Peter Flachenecker
    Department of Neurology, Julius Maximilians University of Wurzburg, Josef Schneider Strasse 11, D 97080 Wurzburg, Germany
    Mult Scler 10:165-9. 2004
    ..Fatigue is one of the most common disabling symptoms in patients with multiple sclerosis (MS), but the putative role of proinflammatory cytokines remains to be elucidated...
  5. ncbi Secondary progressive multiple sclerosis: current knowledge and future challenges
    Marco Rovaris
    Neuroimaging Research Unit, Scientific Institute and University Ospedale San Raffaele, Milan, Italy
    Lancet Neurol 5:343-54. 2006
    ....
  6. ncbi Defining interferon beta response status in multiple sclerosis patients
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, OH 44195, USA
    Ann Neurol 56:548-55. 2004
    ..MRI classification may facilitate rational therapeutic decisions, better clinical trial designs, and studies correlating biomarkers with therapeutic response...
  7. ncbi Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis
    L K Fisniku
    NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, UK
    Brain 131:808-17. 2008
    ..001). The estimated rate of lesion growth over 20 years was 0.80 cm3/year in those who retained a relapsing remitting multiple sclerosis course, and 2...
  8. ncbi Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS
    R Zivadinov
    Department of Clinical Medicine and Neurology, University of Trieste, Italy
    Neurology 57:1239-47. 2001
    ..Furthermore, there are no data on the impact of IVMP on T1 black holes or whole-brain atrophy...
  9. ncbi Long-term follow up of patients with clinically isolated syndromes, relapsing-remitting and secondary progressive multiple sclerosis
    Maja Eriksson
    Institute of Clinical Neuroscience, Sahlgrenska University Hospital, Gothenburg, Sweden
    Mult Scler 9:260-74. 2003
    ..Predictors from this study could be used to refine historically controlled trials...
  10. ncbi Progressive multifocal leukoencephalopathy in a patient treated with natalizumab
    Annette Langer-Gould
    Department of Neurology, Stanford University School of Medicine, Stanford, Calif, USA
    N Engl J Med 353:375-81. 2005
    ..The patient was treated with systemic cytarabine, and two months later, his condition had improved...
  11. ncbi Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis
    Mikael Schwarz
    Glycominds Ltd, Lod 71291, Israel
    J Neurol Sci 244:59-68. 2006
    ..0001). The present findings support further assessment of serum anti-Galpha4Galpha antibodies as a potential biomarker for MS, which may confirm disease diagnosis and aid in its management...
  12. ncbi Natalizumab plus interferon beta-1a for relapsing multiple sclerosis
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    N Engl J Med 354:911-23. 2006
    ..Despite interferon beta therapy, many patients have relapses. Natalizumab, an alpha4 integrin antagonist, appeared to be safe and effective alone and when added to interferon beta-1a in preliminary studies...
  13. pmc The effect of immunomodulatory treatment on multiple sclerosis fatigue
    L M Metz
    Department of Clinical Neurosciences, University of Calgary, Alberta, Canada
    J Neurol Neurosurg Psychiatry 75:1045-7. 2004
    ..To assess the effects of glatiramer acetate and beta interferon on fatigue in multiple sclerosis...
  14. ncbi Immunomodulatory effects of Vitamin D in multiple sclerosis
    Jorge Correale
    Raul Carrea Institute for Neurological Research, FLENI, Montaneses 2325, 1428 Buenos Aires, Argentina
    Brain 132:1146-60. 2009
    ..and thirty-two Hispanic patients with clinically definite multiple sclerosis were studied, 58 with relapsing remitting multiple sclerosis during remission, 34 during relapse and 40 primary progressive multiple sclerosis cases...
  15. ncbi Statins as immunomodulators: comparison with interferon-beta 1b in MS
    O Neuhaus
    Department of Neurology, Multiple Sclerosis Research Group, Karl Franzens Universität, Graz, Austria
    Neurology 59:990-7. 2002
    ..In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)beta-1b...
  16. ncbi Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review
    Annette Langer-Gould
    Department of Health Research and Policy, Stanford University School of Medicine, Stanford, CA 94305, USA
    Arch Neurol 63:1686-91. 2006
    ..To identify clinical and demographic factors associated with long-term disability in patients with relapsing-remitting multiple sclerosis...
  17. pmc Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level
    Koen Venken
    Hasselt University, Biomedisch Onderzoeksinstituut and Transnationale Universiteit Limburg, School of Life Sciences, Diepenbeek, Belgium
    Immunology 123:79-89. 2008
    ..Our results also suggest that Tregs accumulate in the CSF of RR-MS patients, in an attempt to down-regulate local inflammation in the central nervous system...
  18. ncbi Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine
    H Bartosik-Psujek
    Department of Neurology, Medical University, Lublin, Poland
    Acta Neurol Scand 109:390-2. 2004
    ..The aim of the study was to evaluate the effects of immunosuppressive therapy on production of two proinflammatory chemokines--interleukin-8 (IL-8) and RANTES (regulated on activation, normal T cell expressed and secreted)...
  19. ncbi A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis
    Chris H Polman
    Vrije Universiteit Medical Center, Amsterdam, The Netherlands
    N Engl J Med 354:899-910. 2006
    ..Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis...
  20. ncbi A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
    P W O'Connor
    University of Toronto, Ontario, Canada
    Neurology 66:894-900. 2006
    ..In this randomized, double-blind, placebo-controlled Phase II study, the authors examined the safety and efficacy of oral teriflunomide in multiple sclerosis (MS) with relapses...
  21. ncbi Natural history of multiple sclerosis: a unifying concept
    Christian Confavreux
    Service de Neurologie A, the European Database for Multiple Sclerosis EDMUS Coordinating Center and INSERM U 433, Hopital Neurologique, Lyon, France
    Brain 129:606-16. 2006
    ....
  22. ncbi Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis
    G Birnbaum
    MS Treatment and Research Center, Minneapolis Clinic of Neurology, 4225 Golden Valley Road, Golden Valley, MN 55422, USA
    Neurology 71:1390-5. 2008
    ..To explore whether high-dose atorvastatin can be administered safely to persons with relapsing-remitting multiple sclerosis (MS) taking thrice weekly, 44 microg dose subcutaneous interferon beta-1a...
  23. ncbi Oral fingolimod (FTY720) for relapsing multiple sclerosis
    Ludwig Kappos
    Department of Neurology, University Hospital, Basel, Switzerland
    N Engl J Med 355:1124-40. 2006
    ..Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis...
  24. ncbi Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
    B K Kleinschmidt-Demasters
    Department of Pathology, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 353:369-74. 2005
    ..There was extensive tissue destruction and cavitation in the left frontoparietal area, large numbers of bizarre astrocytes, and inclusion-bearing oligodendrocytes, which were positive for JC virus DNA on in situ hybridization...
  25. ncbi Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
    Daniel D Mikol
    University of Michigan Medical Center, Ann Arbor, MI 48109 0316, USA
    Lancet Neurol 7:903-14. 2008
    ..Our aim in the REGARD (REbif vs Glatiramer Acetate in Relapsing MS Disease) study was to compare interferon beta-1a with glatiramer acetate in patients with RRMS...
  26. ncbi Natalizumab effects on immune cell responses in multiple sclerosis
    Masaaki Niino
    Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill University, Quebec, Canada
    Ann Neurol 59:748-54. 2006
    ..Our objective was to study in vivo biological effects of natalizumab on immune cell phenotype and function in multiple sclerosis (MS) patients...
  27. ncbi Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data
    K P Johnson
    Maryland Center for MS, Baltimore, MD 21201, USA
    Acta Neurol Scand 111:42-7. 2005
    ..To assess the long-term effectiveness of continuous glatiramer acetate (GA) therapy in relapsing-remitting multiple sclerosis (RRMS)...
  28. ncbi Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis
    Jordi Rio
    Unitat de Neuroimmunologia Clinica, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Mult Scler 11:306-9. 2005
    ....
  29. ncbi Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS
    L Kappos
    University of Basel, Basel, Switzerland
    Neurology 67:944-53. 2006
    ..c.) interferon (IFN) beta-1a in relapsing-remitting multiple sclerosis (RRMS)...
  30. ncbi Improvement of health-related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon-beta-1a
    Peter Joseph Jongen
    MS4 Research Institute, Ubbergseweg 34, 6522 KJ, Nijmegen, The Netherlands
    J Neurol 257:584-9. 2010
    In patients with relapsing remitting multiple sclerosis (RRMS), the effect of interferon-beta (INFb) on health-related quality of life (HR-QoL) is not firmly documented...
  31. ncbi Cortical demyelination and diffuse white matter injury in multiple sclerosis
    Alexandra Kutzelnigg
    Center for Brain Research, Medical University of Vienna, Vienna, Austria
    Brain 128:2705-12. 2005
    ..With chronicity, diffuse inflammation accumulates throughout the whole brain, and is associated with slowly progressive axonal injury in the NAWM and cortical demyelination...
  32. ncbi Eight-year follow-up study of brain atrophy in patients with MS
    E Fisher
    Whitaker Biomedical Imaging Laboratory, The Cleveland Clinic Foundation, OH 44195, USA
    Neurology 59:1412-20. 2002
    ..The specific goals of this study were to determine if brain atrophy is related to subsequent disability status and to identify MRI correlates of atrophy progression...
  33. ncbi The IgG subclass-specificities of anti-IFNbeta antibodies change with time and differ between the IFNbeta products in relapsing remitting multiple sclerosis patients
    Ebrima Gibbs
    Neuro Immunology Laboratory, Department of Medicine, University of British Columbia, 2211 Wesbrook Mall, Vancouver, BC, Canada
    J Neuroimmunol 190:146-50. 2007
    ..This difference in the levels of IgG3 may help to clarify the differences in the overall pattern of development of anti-IFNbeta antibodies in IFNbeta-1a-and IFNbeta-1b-treated patients...
  34. ncbi Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods
    Valerie M Anderson
    MS NMR Research Unit, University College London, Institute of Neurology, Queen Square, London, UK
    J Neuroimaging 17:61-8. 2007
    ....
  35. ncbi Evidence of early cortical atrophy in MS: relevance to white matter changes and disability
    N De Stefano
    Institute of Neurological Sciences, University of Siena, Italy
    Neurology 60:1157-62. 2003
    ....
  36. ncbi Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: an actigraphic study
    Laura Mendozzi
    Multiple Sclerosis Rehabilitation Unit, Milan, Italy
    Mult Scler 16:238-47. 2010
    ..Poor sleep is common in MS and it contributes to fatigue. The beta interferons produce systemic effects which may not adapt and may induce fatigue...
  37. ncbi Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b
    A B Rao
    Laboratory of Diagnostic Radiology Research, Clinical Center, NIH, Bethesda, MD 20892, USA
    Neurology 59:688-94. 2002
    ..To determine the effect of IV methylprednisolone (IVMP) on brain fraction volume (BFV), contrast-enhancing (CE) lesions, and white matter lesion load (WMLL) in patients with relapsing-remitting MS treated for acute exacerbations...
  38. doi Alemtuzumab vs. interferon beta-1a in early multiple sclerosis
    Alasdair J Coles
    N Engl J Med 359:1786-801. 2008
    ..Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis...
  39. ncbi Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging
    Luca Massacesi
    Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy
    Arch Neurol 62:1843-7. 2005
    ..Azathioprine is an immunosuppressive agent that reduces relapse rates in patients with multiple sclerosis (MS), but its efficacy in suppressing new brain lesions has never been evaluated...
  40. ncbi Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study
    A Prinster
    Biostructure and Bioimaging Institute, National Council for Research, Edificio 10, Via Pansini, 5, 80131 Napoli, Italy
    Neuroimage 29:859-67. 2006
    ..Our findings suggest that in RR-MS cortical GM reduction preferentially involves left fronto-temporal structures and deep GM, the latter correlating preferentially to global lesion load...
  41. ncbi 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
    Paul O'Connor
    St Michael s Hospital, Toronto, Canada
    Lancet Neurol 8:889-97. 2009
    ....
  42. ncbi Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
    N Putzki
    Department of Neurology, University Hospital Essen, Essen, Germany
    Eur J Neurol 16:424-6. 2009
    Natalizumab has been recommended for the treatment of patients with relapsing remitting multiple sclerosis with insufficient response to interferon-beta (IFN-beta) or glatiramer acetate (GA).
  43. ncbi Brain atrophy in clinically early relapsing-remitting multiple sclerosis
    D T Chard
    NMR Research Unit, Department of Clinical Neurology, Institute of Neurology, University College London, UK
    Brain 125:327-37. 2002
    ..The lack of correlation between lesion load measures and WMF suggests that pathological changes in white matter may occur by mechanisms which are at least partly independent from overt lesion genesis in early multiple sclerosis...
  44. ncbi Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis
    Marien Gadea
    Area de Psicobiologia, Facultat de Psicologia, Universitat de Valencia, Avda Blasco Ibáñez 21, E 46010, Valencia, Spain
    Brain 127:89-98. 2004
    ..The use of both 1H-MRS and DL showed the connection between axonal damage at right locus coeruleus and auditive selective attention dysfunction in early-stage RRMS...
  45. ncbi [Mitoxantrone as induction therapy in aggressive relapsing remitting multiple sclerosis: a descriptive analysis of 100 consecutive patients]
    E Le Page
    Service de Neurologie, Hopital Pontchaillou, Rennes
    Rev Neurol (Paris) 162:185-94. 2006
    ..We report an observational study of 100 aggressive relapsing remitting (RR) MS patients treated by induction therapy with MITOX and followed up to 5 years...
  46. ncbi Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results
    Rana Karabudak
    Hacettepe University, Faculty of Medicine, Department of Neurology, Neuroimmunology Unit, 06100 Ankara, Turkey
    J Neurol 251:279-83. 2004
    ..The MMP-9 levels showed no significant changes while TIMP-1 levels gradually and significantly increased during 3rd and 6th months of therapy compared with pretreatment levels...
  47. ncbi Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study
    P Kapeller
    NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    J Neurol 248:131-8. 2001
    ..This preliminary finding should be confirmed in a larger cohort, and follow-up studies are also needed to determine the prognostic and pathophysiological significance of these early changes...
  48. ncbi Elevated serum soluble vascular adhesion protein-1 (VAP-1) in patients with active relapsing remitting multiple sclerosis
    Laura Airas
    Department of Neurology and MediCity Research Laboratory, University of Turku, PO Box 52, 20521Turku, Finland
    J Neuroimmunol 177:132-5. 2006
    ..388+/-102 ng/ml, p=0.0068). We propose that VAP-1 might participate in controlling leukocyte entry into inflamed brain...
  49. ncbi Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison
    Mark S Freedman
    Department of Medicine Neurology, University of Ottawa, Ottawa, Ontario, Canada
    Eur Neurol 60:1-11. 2008
    ..In the absence of head-to-head studies for all products used to treat RRMS, it still may be possible to compare treatment effects by applying evidence-based medicine principles...
  50. ncbi Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study
    Jens Wuerfel
    Institute of Neuroimmunology, Charite, Berlin, Germany
    Brain 127:111-9. 2004
    ..Our data indicate that inflammation is accompanied by altered local perfusion, which can be detected prior to permeability of the BBB...
  51. ncbi Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis
    J Smolders
    School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands
    Mult Scler 14:1220-4. 2008
    ..We investigated the association between serum levels of 25(OH)D and 1,25-dihydroxyvitamin D (1,25(OH)2D), the biologically active metabolite, and clinical MS severity as expressed by EDSS-score and relapse rate...
  52. pmc Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis
    Laure Michel
    INSERM U643, CHU Nantes, Institut de Transplantation et de Recherche en Transplantation ITERT, and Faculté de Médecine, Universite de Nantes, Nantes, France
    J Clin Invest 118:3411-9. 2008
    ..The decreased inhibitory function of unfractioned CD4+CD25high cells previously observed might be due to abnormal activation of CD127high T cells in patients with MS...
  53. ncbi Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis
    R M Valenzuela
    UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Mult Scler 13:754-62. 2007
    ..To determine whether glatiramer acetate (GA)-induced lymphoproliferation and IFN-gamma and IL-4 modulation correlate with the clinical response in multiple sclerosis (MS)...
  54. ncbi Natalizumab for multiple sclerosis
    Richard M Ransohoff
    Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, OH 44195, USA
    N Engl J Med 356:2622-9. 2007
  55. ncbi Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis
    Andreas Hug
    Department of Neurology, University of Heidelberg, Heidelberg, Germany
    J Immunol 171:432-7. 2003
    ..Altogether, our findings suggest that an impaired thymic export function and, as a consequence, altered ability to maintain T cell homeostasis and immune tolerance may play an important pathogenic role in RRMS...
  56. ncbi Clinical characteristics of responders to interferon therapy for relapsing MS
    E Waubant
    UCSF MS Center, San Francisco, CA 94117, USA
    Neurology 61:184-9. 2003
    ..To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-beta (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders...
  57. ncbi A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis
    Claudia C Kaiser
    Department of Anesthesiology, University of Illinois, Chicago, 60612, United States
    J Neuroimmunol 211:124-30. 2009
    ..These results show that pioglitazone was well tolerated in RRMS patients with indications of beneficial effects, warranting further trials to establish clinical efficacy...
  58. ncbi Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial
    Hillel Panitch
    University of Vermont College of Medicine, Neurology Health Care Service, 1 South Prospect Street, Burlington, VT 05401, USA
    J Neurol Sci 239:67-74. 2005
    ..The development of antibodies to IFN was associated with reduced efficacy on MRI measures and fewer IFN-related adverse events, but did not have an impact on relapse outcomes...
  59. ncbi Increased IL-13 but not IL-5 production by CD4-positive T cells and CD8-positive T cells in multiple sclerosis during relapse phase
    Hirofumi Ochi
    Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, 812 8582, Fukuoka, Japan
    J Neurol Sci 201:45-51. 2002
    ..A distinct profile of IL-13 and IL-5 production by disease and by phase of MS suggests an active involvement of these type 2 cytokines in central nervous system (CNS) inflammation...
  60. ncbi Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials
    M Chofflon
    Policlinique de Neurologie, Hopital Cantonal Universitaire, Genève Switzerland
    Eur J Neurol 7:369-80. 2000
    ..Furthermore, as inflammatory brain lesions in MS have been shown to exhibit more extensive and early axonal damage than previously suspected, early treatment may be advisable in order to delay disease progression in RRMS...
  61. pmc Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration
    Isobel A Scarisbrick
    Program for Molecular Neuroscience, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biol Chem 389:739-45. 2008
    ..These novel findings suggest that KLK1 and KLK6 may serve as serological markers of progressive MS and contribute directly to the development of neurological disability by promoting axonal injury and neuron cell death...
  62. ncbi Abnormal ERPs and high frequency bands power in multiple sclerosis
    M Vazquez-Marrufo
    Psychobiology Lab, Department of Experimental Psychology, University of Seville, Seville, Spain
    Int J Neurosci 118:27-38. 2008
    ..The combined analysis of frequency and time domain suggested diverse phenomena that occurred in the MS patient group related with the EEG background or the motivational status...
  63. ncbi The clinical impact of interferon beta antibodies in relapsing-remitting MS
    Paola Perini
    Multiple Sclerosis Centre First Neurology Clinic, Dept of Neurological and Psychiatrical Sciences, University of Padova, Via Giustiniani, 5, 35128 Padova, Italy
    J Neurol 251:305-9. 2004
    ..These findings demonstrate that high titers of both BAbs and NAbs reduce the clinical efficacy of IFNbeta in patients with RRMS, which is important for the long-term efficacy of these drugs...
  64. ncbi Regulatory T cell function correlates with serum 25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D, parathyroid hormone and calcium levels in patients with relapsing remitting multiple sclerosis
    Joost Smolders
    School for Mental Health and Neuroscience, Maastricht University Medical Center, PO Box 616, 6200MD Maastricht, The Netherlands
    J Steroid Biochem Mol Biol 121:243-6. 2010
    ..These results suggest that the serum levels of 1,25(OH)2D, PTH, and total calcium are not critically involved in the correlation between vitamin D status and T cell regulation...
  65. ncbi A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis
    Gavin Giovannoni
    Queen Mary University London, the Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom
    N Engl J Med 362:416-26. 2010
    ..Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis...
  66. ncbi A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis
    Derek Soon
    Department of Neuroinflammation, Institute of Neurology, Queen Square, London, WC1N 3BG, United Kingdom
    J Neurol 254:306-14. 2007
    ..12). There is evidence of a subtle BBB leakage within visibly non-enhancing lesions in RRMS that was not modified by alpha4 integrin blockade in this substudy cohort...
  67. ncbi In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects
    M Ramanathan
    Department of Pharmaceutics, 543 Cooke Hall, State University of New York at Buffalo, 14260 1200, Buffalo, NY, USA
    J Neuroimmunol 116:213-9. 2001
    ..To use DNA arrays to identify differences in gene expression associated with relapsing-remitting (RR) MS...
  68. ncbi Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis
    Jürgen Haas
    Division of Molecular Neuroimmunology, Department of Neurology, University of Heidelberg, Germany
    Eur J Immunol 35:3343-52. 2005
    ..The effect was persistent and not due to responder cell resistance or altered survival of Treg, suggesting that a defective immunoregulation of peripheral T cells mediated by (CD4+)CD25high T lymphocytes promotes CNS autoimmunity in MS...
  69. ncbi Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol
    Samantha S Soldan
    Department of Neurology, Reed Neurological Research Center, University of California School of Medicine, Los Angeles, CA 90095, USA
    J Immunol 171:6267-74. 2003
    ..In a pilot trial, oral estriol treatment of relapsing remitting multiple sclerosis patients caused significant decreases in enhancing lesions on brain magnetic resonance imaging...
  70. ncbi A subtype of multiple sclerosis defined by an activated immune defense program
    L G M van Baarsen
    Department of Molecular Cell Biology and Immunology, VU Medical Center, Amsterdam, The Netherlands
    Genes Immun 7:522-31. 2006
    ....
  71. ncbi Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone
    E L J Hoogervorst
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 8:415-9. 2002
    ..Multiple sderosis (MS) patients develop varying degrees of cerebral atrophy, which may already begin at disease onset The purpose of this study is to examine the effect of steroid treatment on cerebral volume in MS patients...
  72. ncbi Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis
    B Audoin
    NMR Research Unit, Institute of Neurology, University College London, London, UK
    Mult Scler 13:483-9. 2007
    ....
  73. ncbi New natural history of interferon-beta-treated relapsing multiple sclerosis
    Maria Trojano
    Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy
    Ann Neurol 61:300-6. 2007
    ..To investigate the impact of interferon-beta (IFNbeta) on disease progression in relapsing-remitting multiple sclerosis patients...
  74. ncbi Localization of grey matter atrophy in early RRMS : A longitudinal study
    Bertrand Audoin
    NMR Research Group, Institute of Neurology, Queen Square, London, UK
    J Neurol 253:1495-501. 2006
    ..This study suggests that early in the clinical course of RRMS, the thalamic atrophy is more consistently apparent than regional cortical atrophy...
  75. pmc Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis
    M Bieniek
    NMR Research Unit, Institute of Neurology, University College London, London, UK
    J Neurol Neurosurg Psychiatry 77:1036-9. 2006
    ..An improved understanding of the causes of early progressive disability in primary progressive multiple sclerosis (PPMS) could provide mechanistic targets for therapeutic intervention...
  76. ncbi Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease
    J Killestein
    Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
    Mult Scler 7:145-50. 2001
    ....
  77. ncbi Oral simvastatin treatment in relapsing-remitting multiple sclerosis
    Timothy Vollmer
    Barrow Neurological Institute, St Joseph s Hospital and Medical Center, Phoenix, AZ, USA
    Lancet 363:1607-8. 2004
    ..0001) and 41% (p=0.0018), respectively. Treatment was well tolerated. Oral simvastatin might inhibit inflammatory components of multiple sclerosis that lead to neurological disability...
  78. pmc Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis
    Yulin Ge
    Department of Radiology, Center for Biomedical Imaging, New York University School of Medicine, 650 First Ave, Room 615, New York, NY 10016, USA
    Arch Neurol 65:812-6. 2008
    ..Ultrahigh-field (eg, 7-T) magnetic resonance imaging (MRI) has become a tool for assessing vascular involvement in MS lesions owing to markedly increased image resolution and susceptibility contrast of venous blood...
  79. ncbi Abnormal sensorimotor control, but intact force field adaptation, in multiple sclerosis subjects with no clinical disability
    Maura Casadio
    Department of Informatics, Systems and Telematics and Research Centre for Neuroscience and Neuroengineering, University of Genoa, Via Opera Pia 13, Genoa 16145, Italy
    Mult Scler 14:330-42. 2008
    ..This indicates that early in the disease MS subjects have intact adaptive capabilities, but impaired movement execution...
  80. ncbi Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression
    Koen Venken
    Biomedisch Onderzoeksinstituut and Transnationale Universiteit Limburg, School of Life Sciences, Hasselt University, Diepenbeek, Belgium
    J Neurosci Res 83:1432-46. 2006
    ..These data are the first to demonstrate differences in function and FOXP3 expression of CD4(+)CD25(+) T cells from patients with RR- and SP-MS...
  81. ncbi Managing self-injection difficulties in patients with relapsing-remitting multiple sclerosis
    Darcy Cox
    University of California, San Francisco, USA
    J Neurosci Nurs 38:167-71. 2006
    ..Nurses who are familiar with these tools have the opportunity to have a significant positive impact on patient comfort, confidence, and, ultimately, successful long-term adherence to disease-modifying medications...
  82. ncbi Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis
    D T Chard
    NMR Research Unit, Institute of Neurology, University College London, Queen Square, London WC1N 3BG, UK
    Brain 125:2342-52. 2002
    ..The correlation of clinical impairment with a raised NAWM Ins may indicate that glial proliferation also relates to function at this stage of the disease...
  83. ncbi Cladribine tablets: a potential new short-course annual treatment for relapsing multiple sclerosis
    Jack C Sipe
    Associate Professor, Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA
    Expert Rev Neurother 10:365-75. 2010
    ..Assessments and conclusions will include a speculative 5-year outlook...
  84. ncbi Treatment with laquinimod reduces development of active MRI lesions in relapsing MS
    C Polman
    Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands
    Neurology 64:987-91. 2005
    ..The purpose of this study was to evaluate safety, tolerability, and efficacy on MRI lesions of two different doses of laquinimod compared with placebo in patients with relapsing MS...
  85. ncbi Impaired short-term motor learning in multiple sclerosis: evidence from virtual reality
    Letizia Leocani
    Department of Neurology, Clinical Neurophysiology and Neurorehabilitation, University Vita Salute, Scientific Institute Hospital San Raffaele, Milan, Italy
    Neurorehabil Neural Repair 21:273-8. 2007
    ..The objective of this study was to investigate the usefulness of VR in the assessment of short-term motor learning in multiple sclerosis (MS)...
  86. ncbi Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis
    Jason Ramtahal
    The Walton Centre for Neurology and Neurosurgery, Lower Lane, Liverpool L9 7LJ, UK
    J Neurol 253:1160-4. 2006
    ..Acetate appears a safe and effective option for continuing disease modification in patients with relapsing remitting multiple sclerosis treated with Mitoxantrone...
  87. pmc Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis
    M S A Deloire
    EA 2966 Neurobiology of Myelin Disorders Laboratory, University Victor Segalen, Case 78, 146 rue Leo Saignat, 33076 Bordeaux Cedex, France
    J Neurol Neurosurg Psychiatry 76:519-26. 2005
    ....
  88. ncbi Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Ludwig Kappos
    University Hospital Basel, Basel, Switzerland
    Lancet 372:1463-72. 2008
    ..Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis...
  89. pmc Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study
    W Rashid
    MS NMR Research Unit, Department of Neuroinflammation, Institute of Neurology, University College London, Queen Square, London, WC1N 3BG, UK
    J Neurol Neurosurg Psychiatry 77:51-5. 2006
    ..It is less clear how early it can be detected in relapsing-remitting (RR) MS, and whether early cord atrophy relates to the concurrent or future clinical course...
  90. pmc Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis
    Friedemann Paul
    Cecilie Vogt Clinic for Neurology in the HELIOS Clinic Berlin Buch, Charité University Medicine Berlin and Max Delbrueck Center for Molecular Medicine, Berlin, Germany
    PLoS ONE 3:e1928. 2008
    ..Recent data from animal models of multiple sclerosis (MS) and from a pilot study indicated a possible beneficial impact of statins on MS...
  91. pmc Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
    Florian Then Bergh
    Section of Neurology, Max Planck Institut fur Psychiatrie, Munchen, Germany
    BMC Neurol 6:19. 2006
    ..Intermittent IV-MP, alone or with immunomodulators, has been suggested but insufficiently studied as a strategy to prevent relapses...
  92. ncbi A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients
    C C Ford
    MIND Imaging Center, Albuquerque, NM, USA
    Mult Scler 12:309-20. 2006
    A decade of continuous glatiramer acetate (GA) use by relapsing remitting multiple sclerosis (RRMS) patients was evaluated in this ongoing, prospective study, and the neurological status of 'Withdrawn' patients was assessed at a 10-year ..
  93. ncbi Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study
    Richard A Rudick
    Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, OH, USA
    Ann Neurol 60:236-42. 2006
    ..To evaluate the relation between T2 lesions and disease severity in relapsing-remitting multiple sclerosis (MS)...
  94. ncbi Improvement of hand dexterity following motor cortex rTMS in multiple sclerosis patients with cerebellar impairment
    G Koch
    Clinica Neurologica, Dipartimento di Neuroscienze, Universita Tor Vergata, Rome, Italy
    Mult Scler 14:995-8. 2008
    ..rTMS of the motor cortex may be a useful approach to treat cerebellar impairment in MS patients...
  95. ncbi Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates
    Valerie M Anderson
    MS NMR Research Unit, University College London Institute of Neurology, Queen Square, London, WC1N 3BG, UK
    J Neurol 254:1588-94. 2007
    ....
  96. ncbi Emerging oral therapies for multiple sclerosis
    B A Cohen
    Davee Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    Int J Clin Pract 61:1922-30. 2007
    ..Therefore, alternative MS treatments with less invasive routes of administration and new modes of action are needed to expand the current treatment repertoire, increase patient satisfaction and adherence, and thereby improve efficacy...
  97. ncbi The relationship among depression, subjective cognitive impairment, and neuropsychological performance in multiple sclerosis
    L Julian
    University of California, San Francisco, CA, USA
    Mult Scler 13:81-6. 2007
    ..Furthermore, patients may be more accurate reporters of their cognitive impairment after successful treatment for depression, suggesting that depression decreases the accuracy of patient reported cognitive impairment...
  98. ncbi Longitudinal follow-up of "benign" multiple sclerosis at 20 years
    Ana Luiza Sayao
    Department of Medicine Neurology, University of British Columbia, Vancouver, BC, Canada
    Neurology 68:496-500. 2007
    ..To evaluate disease status after 20 years in a cohort defined as "benign multiple sclerosis (MS)" (Expanded Disability Status Scale [EDSS] score < or = 3) at 10 years from onset...
  99. ncbi Genomic effects of IFN-beta in multiple sclerosis patients
    Bianca Weinstock-Guttman
    Jacobs Neurological Institute, Buffalo General Hospital, Buffalo, NY 14203, USA
    J Immunol 171:2694-702. 2003
    ..The findings demonstrate that IFN-beta treatment induces specific and time-dependent changes in multiple mRNAs in lymphocytes of multiple sclerosis patients that could provide a framework for rapid monitoring of the response to therapy...
  100. ncbi A systematic approach to analyse health-related quality of life in multiple sclerosis: the GEDMA study
    J M Morales-Gonzáles
    Department of Research, Ministry of Labour and Social Affairs, Madrid, Spain
    Mult Scler 10:47-54. 2004
    ..To describe a holistic and comprehensive approach to the assessment of sufferer's perceptions of health-related quality of life (HRQoL) in a cohort of multiple sclerosis (MS) patients...
  101. pmc A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis
    R Zivadinov
    Department of Clinical Medicine and Neurology, University of Trieste, Trieste, Italy
    J Neurol Neurosurg Psychiatry 70:773-80. 2001
    ....

Research Grants62

  1. Autoimmunity Center of Excellence - Rochester
    R John Looney; Fiscal Year: 2013
    ..B cell depletion using rituximab has been shown to be effective in rheumatoid arthritis and relapsing remitting multiple sclerosis. We believe that inhibition of B cell migration into target tissues is responsible for much of ..
  2. Mining the Multiple Sclerosis miRNome for Disease Markers
    Amy E Lovett Racke; Fiscal Year: 2010
    ..This study is designed to identify normally occurring microRNA that may be dysregulating, promoting autoimmunity. The data will enable us to identify new therapeutic targets and disease biomarkers for MS. ..
  3. A Controlled Trial of CBT for Multiple Sclerosis Inflammation
    David I Daikh; Fiscal Year: 2010
    ..We also wilt enhance our understanding of mechanisms by examining potential psychosocial, immune, and endocrine mediators of the relationship betweenSLEs and clinical and neuroimaging markers of MS inflammation. ..
  4. Regulation of B-catenin by RPTPB/Z in fetal human glial progenitors
    Crystal R McClain; Fiscal Year: 2012
    ..Therefore, this proposal aims to characterize a novel candidate, pleiotrophin, and its likely contribution to inhibiting glial progenitor differentiation in vitro and in vivo. ..
  5. Tr1-Specific Tolerance: a Novel Treatment of Multiple Sclerosis
    Kanneganti Murthy; Fiscal Year: 2012
    ..These studies will use a combination of actively induced and transfer models of EAE employing myelin-specific 5B6 PLP139-151-specific TCR transgenic T cells. ..
  6. Immunomodulation of Relapsing Remitting Multiple Sclerosis by Gut Parasites
    Zsuzsanna Fabry; Fiscal Year: 2010
    ..NMSS) to test the efficacy of Helminth-induced Immunomodulatory Therapy (HINT) in patients with relapsing remitting multiple sclerosis (RRMS). Helminth-therapy, using T...
  7. Characterization of Symptom Occurrence in Persons with Multiple Sclerosis
    Pamela K Newland; Fiscal Year: 2012
    ..This study is part of a larger mentored training program which includes structured mentorship, coursework, and other training activities to facilitate Dr. Newland's development as an independent nurse researcher. ..
  8. The role of mast cells in relapsing-remitting EAE
    Margaret E Walker; Fiscal Year: 2013
    ..This research specifically focuses on this most clinically relevant disease model for human MS in order to identify novel therapeutic targets. ..
  9. ORAL IFN ALPHA--BIOLOGICAL EFFECTS IN MULTIPLE SCLEROSIS
    Staley Brod; Fiscal Year: 1999
    ..Ingested IFN-alpha may provide superior efficacy and safety in comparison to parenteral administered Type-1 IFNs in RR-MS and other autoimmune diseases. ..
  10. ORAL TOLERANCE TO MYELIN ANTIGENS IN EAE
    Howard Weiner; Fiscal Year: 1993
    ..relevance as there currently are ongoing trials at our institution treating patients with early relapsing remitting multiple sclerosis via oral tolerization to myelin antigens...
  11. The Role of Mast in a Model of Relapsing-Remitting Multiple Sclerosis
    BLAYNE A SAYED; Fiscal Year: 2010
    ..In this application, we will use an established model of relapsing-remitting multiple sclerosis to examine some of the potential mechanisms that underlie mast cell effects on a disease course. ..
  12. EXTRAMURAL RESEARCH FACILITIES IMPROVEMENT PROGRAM GCRC
    Richard Rudick; Fiscal Year: 2003
    ..The expected outcome of this construction project will be a centralized facility to conduct innovative, collaborative clinical research protocols and train a new generation of physician scientists. ..
  13. Case/Cleveland Clinic Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2007
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. [unreadable] [unreadable]..
  14. Case/Cleveland Clinical Research Training Program (RMI)
    Richard Rudick; Fiscal Year: 2004
    ..It will host a national conference on this theme during 2007 to exchange "lessons learned" and evaluate how NIH-sponsored programs are measuring up to this strategic goal. ..
  15. Physical Activity and Quality of Life in Multiple Sclerosis
    Robert Motl; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  16. IN VIVO TREATMENT OF EAE WITH ANTI I-A ANTIBODIES
    Lawrence Steinman; Fiscal Year: 2001
    ..Aim 5 is to assess the possibility of using DNA vaccination against TCR Vb for treatment of EAE. It is hoped that these studies will provide the basis for future clinical trials in MS patients. ..
  17. PEPTIDE MEDIATED IMMUNOTHERAPY FOR AUTOIMMUNE DISEASE
    Lawrence Steinman; Fiscal Year: 2003
    ..This work with APL may be applicable not only to MS, but to other autoimmune diseases including juvenile diabetes, rheumatoid arthritis, and inflammatory bowel disease. ..
  18. Large Scale Images of Gene Transcription in MS and EAE
    Lawrence Steinman; Fiscal Year: 2004
    ..The discovery of the role of osteopontin, first identified in large scale profiles, exemplifies how this approach may help us to understand MS and to develop new therapies. ..
  19. Pregnancy and the Modulation of Multiple Sclerosis
    Annette Langer Gould; Fiscal Year: 2006
    ..The search for the pregnancy-related factor or hormone responsible for the protective effect of pregnancy in MS may potentially lead to the development of novel treatments for MS and other Th1-driven autoimmune diseases. ..
  20. Brain Atrophy/Diffusion Tensor Study/Multiple Sclerosis
    Robert Fox; Fiscal Year: 2008
    ..Furthermore, these studies should help develop improved methods for evaluating new therapeutic strategies for neuroprotection and neuroregeneration. ..
  21. Diffusion Tensor Imaging of Wallerian Degeneration in MS
    Khader Hasan; Fiscal Year: 2009
    ..This tool will also help in the fusion of multi-modal MRI data for a robust segmentation of the subregions of CC and 1C. The DTI measures, after accounting for the age and gender dependence will be correlated with the clinical measures. ..
  22. Using the Internet to Improve Patient's Self-Management of Chronic Illness
    Deborah Miller; Fiscal Year: 2006
    ..The utilization analysis will allow us to identify the incremental benefit of the comprehensive system compared to the secure system and to determine where there greatest savings in overall cost of care is gained. ..
  23. HSP60 ABNORMALITIES IN SCHIZOPHRENIA
    Saud Sadiq; Fiscal Year: 2001
    ..Molecular studies will involve genomic and cDNA cloning of hsp60 from peripheral and brain tissue. Epitope mapping will be done by ELISA using overlapping peptides spanning the entire normal human hsp60 sequence. ..
  24. Caveolin-1/lGF-IR Interactions in Oligodendrocytes
    Daniel Mikol; Fiscal Year: 2004
    ..Understanding the interplay between the IGF-IR and caveolin-1 and their control of OLG phenotype will provide insight into the molecular basis of myelination by OLGs and, hopefully, guide new treatments for MS. ..
  25. T cell activation requirement in autoimmune demyelination
    Michael K Racke; Fiscal Year: 2010
    ..In addition, we will examine the production of IL-17-producing T cells from patients with multiple sclerosis and determine whether the current immunomodulatory therapies affect secretion of this cytokine. ..
  26. HIV Neuroprotection Workshop
    Joseph Berger; Fiscal Year: 2004
    ..The proposed conference is the first of its kind to highlight neuroprotection in HIV CNS and PNS disorders. By coupling this meeting with the International Symposium on Neurovirology this synergy can be exploited. ..
  27. NEUROSCIENCE OF HIV CONFERENCE
    Joseph Berger; Fiscal Year: 2002
    ..Dr. Brian Wigdahl, international co-chair of the ISNV, is a co-investigator on this grant. ..
  28. MR PREDICTORS OF RESPONSE TO HAART IN HIV DEMENTIA
    Joseph Berger; Fiscal Year: 2004
    ..It will also open novel avenues for exploring the differential sensitivities of these pathways to HAART, and suggest unique therapeutic options. ..
  29. JCV Virus Expression in Oropharynx and HIV
    Joseph Berger; Fiscal Year: 2004
    ..This line of investigation would add credence to an oropharyngeal mechanism of JCV transmission and may ultimately lead to the clinical identification of an acute illness attributable to this pathogen. ..
  30. MYELINATION--ASSEMBLY OF LIPIDS AND PROTEINS
    JOYCE BENJAMINS; Fiscal Year: 2003
    ..abstract_text> ..
  31. Gender differences in immune responses in MS
    Richard Ransohoff; Fiscal Year: 2009
    ....
  32. Novel Clinical and Ocular Imaging Outcomes with Long-Term Follow-Up in MS
    Laura Balcer; Fiscal Year: 2010
    ..Aim 3: Determine how low-contrast letter acuity, RNFL thickness, and total macular volume impact vision specific and overall health-related quality of life (HRQOL) in longitudinal studies of MS and ON. ..
  33. Cellular Mechanisms for Oligodendrocyte Myelination
    Bruce D Trapp; Fiscal Year: 2010
    ..Collectively, these studies should identify therapeutic targets that enhance remyelination and reduce the progression of neurological disability in MS patients. ..
  34. Assessment of Penile Autonomic Innervation
    Claire Yang; Fiscal Year: 2007
    ..The ability to detect cavernous neuropathy is relevant to the evaluation of erectile dysfunction, as well as the development of disease-specific treatments for neurogenic erectile dysfunction. [unreadable] [unreadable]..
  35. ANNUAL MRI, MTR AND HMRSI IN HEALTHY CONTROLS AND PPMS
    Stephen Hauser; Fiscal Year: 2001
    ....
  36. Treatment of Autoimmune Disease by Costimulatory Signal*
    Samia Khoury; Fiscal Year: 2007
    ..The data obtained from the clinical trials and the critical information from the basic science projects will be valuable in getting us closer to our goal of tolerance induction for autoimmune disease. ..
  37. HIGHER SPEED, FIELD & SPATIAL RESOLUTION BRAIN 3D 1H MRS
    Oded Gonen; Fiscal Year: 2001
    ..Since expensive, fast shielded-gradients are not intrinsically required, the proposed research will make multivoxel brain 1H MRS accessible to sites not yet equipped with them. ..
  38. Quantifying Radiation-Therapy Brain Injury With 1H-MRS
    Oded Gonen; Fiscal Year: 2003
    ..H2: That WBNAA is more sensitive than MMSE to detect neuronal injury consequences of WBRT. H3: That this neuronal injury may be transient, in part, and could resolve within several months after WBRT. ..
  39. Role and Mechanism of PDI-PDL Pathway in EAE
    Samia Khoury; Fiscal Year: 2007
    ..We will define the interactions between the PD1 pathway and other CD28 homologues (CD28, CTLA4, ICOS) in regulating EAE. ..
  40. Modulation of type I diabetes with NKT cells
    Luc Van Kaer; Fiscal Year: 2006
    ..These studies will provide a better understanding of the immunological mechanisms that result in autoimmunity, and may lead to the development of novel agents for treatment of type I diabetes and other autoimmune diseases. ..
  41. THE ROLE OF B CELLS IN EAE PATHOGENESIS
    Anne Cross; Fiscal Year: 2004
    ..Methods to alter in humans the number and function of B cells and Abs already exist, making our results potentially applicable to MS therapy. ..
  42. Visual Dysfunction and Quality of Life in MS
    Laura Balcer; Fiscal Year: 2003
    ..This proposal will provide a crucial foundation for future studies of vision in MS that will involve longitudinal assessment. ..
  43. DNA Tolerizing Vaccine Therapy for Multiple Sclerosis
    Hideki Garren; Fiscal Year: 2002
    ..S. FDA for the evaluation of a DNA tolerizing vaccine in a phase I clinical trial. ..
  44. Excerise, Aging, and Psychological Function
    Edward McAuley; Fiscal Year: 2003
    ..As such, the proposed study represents a unique attempt to further understand the role played by physical activity in the psychological health of older Americans. ..
  45. PERSONS WITH DISABILITIES: QUALITY OF CARE/SERVICE USE
    Lisa Iezzoni; Fiscal Year: 2001
    ..Given that roughly 49 million Americans have a disabling condition, addressing concerns about their quality of care is essential. ..
  46. IMMUNOREGULATORY EFFECTS OF ESTROGEN IN EAE
    Halina Offner; Fiscal Year: 2010
    ..E2 in relapsing, chronic, and spontaneous models of EAE. These studies will clearly establish E2- and EE- dependent pathways of EAE protection and therapy that may have direct relevance for future clinical trials in MS patients. ..
  47. Design & Synthesis of Novel CNS-Active Oxytocin and Vasopressin Receptor Ligands
    Edward Roberts; Fiscal Year: 2010
    ....
  48. ASSESSING THE PERFORMANCE OF ALTERNATIVE RISK ADJUSTERS
    Lisa Iezzoni; Fiscal Year: 2001
    ..abstract_text> ..
  49. Molecular Libraries Screening Centers Network (MLSCN)(RMI)
    Hugh Rosen; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  50. Longitudinal Assessment of Visual Function in MS
    Laura Balcer; Fiscal Year: 2007
    ....
  51. S1P Receptor subtypes: Regulating lymphocyte trafficking
    Hugh Rosen; Fiscal Year: 2008
    ..These studies will yield an enhanced understanding of the basic mechanisms by which S1P receptor agonism induces clinically useful immunosuppression of potential use in autoimmunity. ..
  52. ENDOCANNABINOID BIOMARKERS OF OBESITY USING INTEGRATED GENOMICS AND METABOLOMICS
    JACK SIPE; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  53. A PHASE ll TRIAL OF RITUXAN IN MULTIPLE SCLEROSIS
    DOROTHY CROSS; Fiscal Year: 2007
    ..Parks and Naismith, and PI will be able to focus 30% more time on investigator-initiated trials and mentoring junior colleagues. ..
  54. Novel MRI and 1H-MRS markers in Primary Progressive MS
    Matilde Inglese; Fiscal Year: 2009
    ..Letter of support: Prof. John DeLuca, consultant PHS 398 (Rev. 05/01) Page. Form Page 3 Use /2-inch MARGINS. Number pages consecutively at the bottom throughout the application. Do not use suffixes such as 3a, 3b. ..
  55. Serial Brain 3D 1H MR Spectroscopy in Multiple Sclerosis
    Oded Gonen; Fiscal Year: 2009
    ....
  56. Depression, Cytokines, and Pancreatic Cancer
    William Breitbart; Fiscal Year: 2006
    ..abstract_text> ..
  57. Fish oil & alpha lipoic acid in mild Alzheimer's disease
    Lynne Shinto; Fiscal Year: 2004
    ..Compliance of fish oil supplementation will be assessed by red blood cell membrane fatty acid analysis. ..
  58. FAAH GENE MUTATIONS: RISK FACTORS IN DRUG USE/ADDICTION
    JACK SIPE; Fiscal Year: 2006
    ..abstract_text> ..
  59. MRI T2 shortening ('blackT2') in multiple sclerosis
    Rohit Bakshi; Fiscal Year: 2003
    ..Alternatively, if iron accumulation is a disease epiphenomenon, then BT2 could be used as a noninvasive marker of brain degeneration. ..